Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Differentiation agents increase the potential AraC therapy of AML by reactivating cell death pathways without enhancing ROS generation.

Wang X, Dawod A, Nachliely M, Harrison JS, Danilenko M, Studzinski GP.

J Cell Physiol. 2019 Jun 27. doi: 10.1002/jcp.28996. [Epub ahead of print]

PMID:
31245853
2.

Synergistic Cytotoxicity of Methyl 4-Hydroxycinnamate and Carnosic Acid to Acute Myeloid Leukemia Cells via Calcium-Dependent Apoptosis Induction.

Trachtenberg A, Muduli S, Sidoryk K, Cybulski M, Danilenko M.

Front Pharmacol. 2019 May 9;10:507. doi: 10.3389/fphar.2019.00507. eCollection 2019.

3.

Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.

Nachliely M, Trachtenberg A, Khalfin B, Nalbandyan K, Cohen-Lahav M, Yasuda K, Sakaki T, Kutner A, Danilenko M.

J Steroid Biochem Mol Biol. 2019 Apr;188:8-16. doi: 10.1016/j.jsbmb.2018.11.017. Epub 2018 Nov 30.

PMID:
30508646
4.

Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen.

Wang X, Nachliely M, Harrison JS, Danilenko M, Studzinski GP.

J Steroid Biochem Mol Biol. 2019 Mar;187:166-173. doi: 10.1016/j.jsbmb.2018.11.015. Epub 2018 Nov 30.

PMID:
30508644
5.

Cardiolipin mediates curcumin interactions with mitochondrial membranes.

Ben-Zichri S, Kolusheva S, Danilenko M, Ossikbayeva S, Stabbert WJ, Poggio JL, Stein DE, Orynbayeva Z, Jelinek R.

Biochim Biophys Acta Biomembr. 2019 Jan;1861(1):75-82. doi: 10.1016/j.bbamem.2018.10.016. Epub 2018 Oct 31.

PMID:
30389425
6.

Diverse assays from a single skin punch biopsy to assess topical drug intervention.

Danilenko M, Hodgson K, Stones R, Husain A, Zangarini M, Veal G, Rajan N.

Br J Dermatol. 2019 Apr;180(4):937-938. doi: 10.1111/bjd.17353. Epub 2019 Jan 20. No abstract available.

7.

Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.

Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N.

JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610.

8.

Transcriptomic profiling of human skin biopsies in the clinical trial setting: A protocol for high quality RNA extraction from skin tumours.

Danilenko M, Stones R, Rajan N.

Wellcome Open Res. 2018 Apr 23;3:45. doi: 10.12688/wellcomeopenres.14360.1. eCollection 2018.

9.

A composition of medicinal plants with an enhanced ability to suppress microsomal lipid peroxidation and a protective activity against carbon tetrachloride-induced hepatotoxicity.

Aralbaeva AN, Mamataeva AT, Zhaparkulova NI, Utegalieva RS, Khanin M, Danilenko M, Murzakhmetova MK.

Biomed Pharmacother. 2017 Dec;96:1283-1291. doi: 10.1016/j.biopha.2017.11.085. Epub 2017 Nov 21.

PMID:
29169731
10.

Development and validation of LC-MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors.

Zangarini M, Rajan N, Danilenko M, Berry P, Traversa S, Veal GJ.

Bioanalysis. 2017 Feb;9(3):279-288. doi: 10.4155/bio-2016-0199. Epub 2017 Jan 23.

11.

A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior.

Ehrmann I, Gazzara MR, Pagliarini V, Dalgliesh C, Kheirollahi-Chadegani M, Xu Y, Cesari E, Danilenko M, Maclennan M, Lowdon K, Vogel T, Keskivali-Bond P, Wells S, Cater H, Fort P, Santibanez-Koref M, Middei S, Sette C, Clowry GJ, Barash Y, Cunningham MO, Elliott DJ.

Cell Rep. 2016 Dec 20;17(12):3269-3280. doi: 10.1016/j.celrep.2016.12.002.

12.

Binding site density enables paralog-specific activity of SLM2 and Sam68 proteins in Neurexin2 AS4 splicing control.

Danilenko M, Dalgliesh C, Pagliarini V, Naro C, Ehrmann I, Feracci M, Kheirollahi-Chadegani M, Tyson-Capper A, Clowry GJ, Fort P, Dominguez C, Sette C, Elliott DJ.

Nucleic Acids Res. 2017 Apr 20;45(7):4120-4130. doi: 10.1093/nar/gkw1277.

13.

Cooperative antiproliferative and differentiation-enhancing activity of medicinal plant extracts in acute myeloid leukemia cells.

Zhamanbayeva GT, Aralbayeva AN, Murzakhmetova MK, Tuleukhanov ST, Danilenko M.

Biomed Pharmacother. 2016 Aug;82:80-9. doi: 10.1016/j.biopha.2016.04.062. Epub 2016 May 7.

PMID:
27470342
14.

Prodifferentiation Activity of Novel Vitamin D₂ Analogs PRI-1916 and PRI-1917 and Their Combinations with a Plant Polyphenol in Acute Myeloid Leukemia Cells.

Nachliely M, Sharony E, Bolla NR, Kutner A, Danilenko M.

Int J Mol Sci. 2016 Jul 5;17(7). pii: E1068. doi: 10.3390/ijms17071068.

15.

Cancer-selective cytotoxic Ca2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid.

Pesakhov S, Nachliely M, Barvish Z, Aqaqe N, Schwartzman B, Voronov E, Sharoni Y, Studzinski GP, Fishman D, Danilenko M.

Oncotarget. 2016 May 31;7(22):31847-61. doi: 10.18632/oncotarget.7240.

16.

Keep Harm at Bay: Oxidative Phosphorylation Induces Nrf2-Driven Antioxidant Response Via ERK5/MEF2/miR-23a Signaling to Keap-1.

Danilenko M, Studzinski GP.

EBioMedicine. 2016 Jan 11;3:4-5. doi: 10.1016/j.ebiom.2016.01.009. eCollection 2016 Jan. No abstract available.

17.

Structural basis of RNA recognition and dimerization by the STAR proteins T-STAR and Sam68.

Feracci M, Foot JN, Grellscheid SN, Danilenko M, Stehle R, Gonchar O, Kang HS, Dalgliesh C, Meyer NH, Liu Y, Lahat A, Sattler M, Eperon IC, Elliott DJ, Dominguez C.

Nat Commun. 2016 Jan 13;7:10355. doi: 10.1038/ncomms10355.

18.

Novel analogs of 1,25-dihydroxyvitamin D2 combined with a plant polyphenol as highly efficient inducers of differentiation in human acute myeloid leukemia cells.

Nachliely M, Sharony E, Kutner A, Danilenko M.

J Steroid Biochem Mol Biol. 2016 Nov;164:59-65. doi: 10.1016/j.jsbmb.2015.09.014. Epub 2015 Sep 10.

PMID:
26365556
19.

The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity.

Linnewiel-Hermoni K, Khanin M, Danilenko M, Zango G, Amosi Y, Levy J, Sharoni Y.

Arch Biochem Biophys. 2015 Apr 15;572:28-35. doi: 10.1016/j.abb.2015.02.018. Epub 2015 Feb 21.

PMID:
25711533
20.

Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia.

Studzinski GP, Harrison JS, Wang X, Sarkar S, Kalia V, Danilenko M.

J Cell Biochem. 2015 Aug;116(8):1500-12. doi: 10.1002/jcb.25104.

PMID:
25694395
21.

The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage.

Wang X, Pesakhov S, Harrison JS, Kafka M, Danilenko M, Studzinski GP.

Exp Cell Res. 2015 Jan 1;330(1):199-211. doi: 10.1016/j.yexcr.2014.10.003. Epub 2014 Oct 16.

22.

Antitumor activity of ethanol extract from Hippophae rhamnoides L. leaves towards human acute myeloid leukemia cells in vitro.

Zhamanbaeva GT, Murzakhmetova MK, Tuleukhanov ST, Danilenko MP.

Bull Exp Biol Med. 2014 Dec;158(2):252-5. doi: 10.1007/s10517-014-2734-3. Epub 2014 Nov 30.

PMID:
25432283
23.

Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons.

Best A, James K, Dalgliesh C, Hong E, Kheirolahi-Kouhestani M, Curk T, Xu Y, Danilenko M, Hussain R, Keavney B, Wipat A, Klinck R, Cowell IG, Cheong Lee K, Austin CA, Venables JP, Chabot B, Santibanez Koref M, Tyson-Capper A, Elliott DJ.

Nat Commun. 2014 Sep 11;5:4760. doi: 10.1038/ncomms5760.

24.

Tra2 protein biology and mechanisms of splicing control.

Best A, Dalgliesh C, Kheirollahi-Kouhestani M, Danilenko M, Ehrmann I, Tyson-Capper A, Elliott DJ.

Biochem Soc Trans. 2014 Aug;42(4):1152-8. doi: 10.1042/BST20140075. Review.

PMID:
25110018
25.

Murine Joubert syndrome reveals Hedgehog signaling defects as a potential therapeutic target for nephronophthisis.

Hynes AM, Giles RH, Srivastava S, Eley L, Whitehead J, Danilenko M, Raman S, Slaats GG, Colville JG, Ajzenberg H, Kroes HY, Thelwall PE, Simmons NL, Miles CG, Sayer JA.

Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9893-8. doi: 10.1073/pnas.1322373111. Epub 2014 Jun 19.

26.

Distribution of antigen-presenting cells CD68 in papillomavirus infection in the skin.

Reva IV, Reva GV, Yamamoto T, Girya OY, Grakhova NV, Maloman NY, Danilenko MV.

Bull Exp Biol Med. 2014 May;157(1):56-61. doi: 10.1007/s10517-014-2491-3. Epub 2014 Jun 11.

PMID:
24915947
27.

ERK 5/MAPK pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal differentiation of myeloid leukemia cells.

Wang X, Pesakhov S, Weng A, Kafka M, Gocek E, Nguyen M, Harrison JS, Danilenko M, Studzinski GP.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:223-7. doi: 10.1016/j.jsbmb.2013.10.002. Epub 2013 Oct 26. Review.

28.

ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells.

Wang X, Pesakhov S, Harrison JS, Danilenko M, Studzinski GP.

J Cell Physiol. 2014 Jul;229(7):856-67. doi: 10.1002/jcp.24513.

29.

The splicing landscape is globally reprogrammed during male meiosis.

Schmid R, Grellscheid SN, Ehrmann I, Dalgliesh C, Danilenko M, Paronetto MP, Pedrotti S, Grellscheid D, Dixon RJ, Sette C, Eperon IC, Elliott DJ.

Nucleic Acids Res. 2013 Dec;41(22):10170-84. doi: 10.1093/nar/gkt811. Epub 2013 Sep 12.

30.

The tissue-specific RNA binding protein T-STAR controls regional splicing patterns of neurexin pre-mRNAs in the brain.

Ehrmann I, Dalgliesh C, Liu Y, Danilenko M, Crosier M, Overman L, Arthur HM, Lindsay S, Clowry GJ, Venables JP, Fort P, Elliott DJ.

PLoS Genet. 2013 Apr;9(4):e1003474. doi: 10.1371/journal.pgen.1003474. Epub 2013 Apr 25.

31.
32.

Differentiation and cell survival of myeloid leukemia cells.

Studzinski GP, Brown G, Danilenko M, Hughes P, Marcinkowska E.

Leuk Res Treatment. 2012;2012:370375. doi: 10.1155/2012/370375. Epub 2012 Jul 31. No abstract available.

33.

The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention.

Sharoni Y, Linnewiel-Hermoni K, Zango G, Khanin M, Salman H, Veprik A, Danilenko M, Levy J.

Am J Clin Nutr. 2012 Nov;96(5):1173S-8S. doi: 10.3945/ajcn.112.034645. Epub 2012 Oct 10. Review.

PMID:
23053550
34.

Carotenoids and apocarotenoids in cellular signaling related to cancer: a review.

Sharoni Y, Linnewiel-Hermoni K, Khanin M, Salman H, Veprik A, Danilenko M, Levy J.

Mol Nutr Food Res. 2012 Feb;56(2):259-69. doi: 10.1002/mnfr.201100311. Epub 2011 Nov 21. Review.

PMID:
22102431
35.

Polyphenols, isothiocyanates, and carotenoid derivatives enhance estrogenic activity in bone cells but inhibit it in breast cancer cells.

Veprik A, Khanin M, Linnewiel-Hermoni K, Danilenko M, Levy J, Sharoni Y.

Am J Physiol Endocrinol Metab. 2012 Oct 1;303(7):E815-24. doi: 10.1152/ajpendo.00142.2011. Epub 2011 Aug 30.

36.

The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.

Bobilev I, Novik V, Levi I, Shpilberg O, Levy J, Sharoni Y, Studzinski GP, Danilenko M.

Cancer Biol Ther. 2011 Feb 1;11(3):317-29. Epub 2011 Feb 1.

38.

Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells.

Pesakhov S, Khanin M, Studzinski GP, Danilenko M.

Nutr Cancer. 2010;62(6):811-24. doi: 10.1080/01635581003693082.

39.
40.

DNA damage response: a barrier or a path to tumor progression?

Studzinski GP, Wang X, Danilenko M.

Cancer Biol Ther. 2010 Feb;9(3):253-5. Epub 2010 Feb 10. No abstract available.

41.
42.

Structure activity relationship of carotenoid derivatives in activation of the electrophile/antioxidant response element transcription system.

Linnewiel K, Ernst H, Caris-Veyrat C, Ben-Dor A, Kampf A, Salman H, Danilenko M, Levy J, Sharoni Y.

Free Radic Biol Med. 2009 Sep 1;47(5):659-67. doi: 10.1016/j.freeradbiomed.2009.06.008. Epub 2009 Jun 11.

PMID:
19524036
43.

Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Shabtay A, Sharabani H, Barvish Z, Kafka M, Amichay D, Levy J, Sharoni Y, Uskokovic MR, Studzinski GP, Danilenko M.

Oncology. 2008;75(3-4):203-14. doi: 10.1159/000163849. Epub 2008 Oct 14.

44.

Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds.

Kim SH, Danilenko M, Kim TS.

Br J Pharmacol. 2008 Nov;155(6):814-25. doi: 10.1038/bjp.2008.319. Epub 2008 Aug 25.

45.

Membrane processes and biophysical characterization of living cells decorated with chromatic polydiacetylene vesicles.

Groysman N, Orynbayeva Z, Katz M, Kolusheva S, Khanin M, Danilenko M, Jelinek R.

Biochim Biophys Acta. 2008 May;1778(5):1335-43. doi: 10.1016/j.bbamem.2008.01.028. Epub 2008 Feb 19.

46.
47.

Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.

Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GL.

Mol Cancer Res. 2007 Jan;5(1):95-108.

48.

Lycopene and other carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells.

Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y.

Breast Cancer Res Treat. 2007 Aug;104(2):221-30. Epub 2006 Oct 19.

PMID:
17051425
49.

Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1.

Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, Sutherland RL, Levy J, Sharoni Y.

Eur J Nutr. 2006 Aug;45(5):275-82. Epub 2006 Mar 24.

PMID:
16565789
50.

Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Sharabani H, Izumchenko E, Wang Q, Kreinin R, Steiner M, Barvish Z, Kafka M, Sharoni Y, Levy J, Uskokovic M, Studzinski GP, Danilenko M.

Int J Cancer. 2006 Jun 15;118(12):3012-21.

Supplemental Content

Loading ...
Support Center